Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hyaluronidase
Drug ID BADD_D01078
Description Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.[L13338] The action of hyaluronidase was first described in 1936, and named in 1939.[A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue.[A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.[A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]
Indications and Usage Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography.[L13338] Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.[L13338]
Marketing Status approved
ATC Code B06AA03
DrugBank ID DB14740
KEGG ID D04455; D04456; D06604
MeSH ID D006821
PubChem ID 91820602
TTD Drug ID D04GPZ
NDC Product Code 0548-9090; 51662-1555; 52221-201
UNII Not Available
Synonyms Hyaluronoglucosaminidase | Hyaluronidase | Hyaglosidase | Hyaluronate Hydrolase | Hydrolase, Hyaluronate | Duran-Reynals Permeability Factor | Duran Reynals Permeability Factor | Factor, Duran-Reynals Permeability | Permeability Factor, Duran-Reynals | GL Enzyme | Wydase
Chemical Information
Molecular Formula C17H24BrNO2
CAS Registry Number 9001-54-1
SMILES CC1(C(=C)N(C2=CC=CC=C21)CCCCCC(=O)O)C.Br
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Urticaria10.01.06.001; 23.04.02.001--
The 1th Page    1    Total 1 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene